A federal judge in Texas has made a significant ruling against the Food and Drug Administration (FDA) regarding the regulation of lab-developed tests. The judge sided with lab trade groups, stating that the FDA was overstepping its bounds with its plan to regulate these tests.
In the ruling, the judge completely invalidated the FDA’s Final Rule titled “Medical Devices; Laboratory Developed Tests.” The matter has been remanded to the Secretary of Health and Human Services for further consideration. This decision effectively halts the FDA’s efforts to regulate lab-developed tests as medical devices.
The FDA has long believed that it has the authority to regulate lab-developed tests, but historically, it has not enforced this regulation. It was only under the Biden administration that the agency announced its intention to actively regulate these tests, giving labs until 2028 to comply. This move came after Congress attempted, but failed, to grant the FDA more explicit authority in 2022.
This ruling has significant implications for the future of lab-developed tests and the FDA’s regulatory authority. It remains to be seen how the agency will respond to this setback and whether it will pursue alternative avenues to regulate these tests in the future.
For more detailed analysis and exclusive content on this topic, readers can subscribe to STAT+ for access to premium articles, newsletters, events, and news alerts. Subscribers will gain valuable insights and in-depth coverage of this evolving story.
